Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas
This study has been terminated.
Study NCT00023166   Information provided by Enzon Pharmaceuticals, Inc.
First Received: August 24, 2001   Last Updated: June 23, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Neoplasm
Lymphomas
Neoplasm Metastasis
Additional conditions recognized in this trial
Lymphoma
Neoplasms
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Neoplastic Processes
Pathologic Processes
Interventions listed in this trial
PEG-paclitaxel
Additional drug interventions recognized in this trial
Paclitaxel
More general drug interventions related to this trial
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
Enzon Pharmaceuticals, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services